Lantern Pharma Inc. Securities Loaned, Fair Value of Collateral
Lantern Pharma Inc. (LTRN) had Securities Loaned, Fair Value of Collateral of $14.20 million as of 2021-06-30, per its 10-Q filed 2021-07-29.
Discontinued › Notes
us-gaap:SecuritiesLoanedFairValueOfCollateral · last filed 2021-07-29
- 2021-06-30: Securities Loaned, Fair Value of Collateral $14.20M.
| Period end | Securities Loaned, Fair Value of Collateral |
|---|---|
| 2021-06-30 | $14.20M 10-Q · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |